Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Virgil A. Place is active.

Publication


Featured researches published by Virgil A. Place.


International Journal of Std & Aids | 2004

Treatment of erectile dysfunction

Virgil A. Place; Robert M. Gale; Randall G. Berggren

Erectile dysfunction (ED) is an inability to attain or maintain an erection sufficient for satisfactory sexual intercourse. It is an undertreated and underdiagnosed condition that can be due to vasculogenic, neurogenic, hormonal and psychogenic factors. Effective treatment of ED should restore quality of life and allow patients to return to the sex life they had before. Current therapeutic options include non-pharmacological treatments, locally administered drugs and oral therapies. The oral phosphodiesterase-5 (PDE5) inhibitors are considered first-line treatments of ED and have revolutionized ED management in the last five years. Three PDE5 inhibitors are currently available, sildenafil, vardenafil and tadalafil. They are all effective with similar efficacy and good safety profiles. However, tadalafil has the added benefit of a broad window opportunity offering patients more freedom to choose when to initiate sexual activity.


International Journal of Pharmaceutics | 1991

In vivo percutaneous penetration/absorption: Sponsored by the American Association of Pharmaceutical Scientist, U.S. Food and Drug Administration, American Academy of Dermatology, Skin Pharmacology Society and the U.S. Army Environmental Hygiene Agency May 1–3, 1989, Washington, DC

Vinod P. Snah; Gordon L. Flynn; Richard H. Guy; Howard I. Maibach; Hans Schaefer; Jerome P. Skelly; Ronald C. Wester; Avraham Yacobi; Bradley D. Anderson; Klaus Ejner Andersen; Brian W. Barry; Charan R. Behl; Leslie Z. Benet; Robert L. Bronaugh; Daniel A. W. Bucks; Annette L. Bunge; Yie W. Chien; Carnot Evans; Thomas J. Franz; William R. Good; William I. Higuchi; Robert Langer; Jean-Paul Marty; Gabriela Nicolau; Esther Patrick; Carl C. Peck; Lynn K. Pershing; Virgil A. Place; Boyd J. Poulsen; Jim E. Riviere

Abstract This workshop, ‘In Vivo Percutaneous Penetration/Absorption’ was held in Washington, DC, on May 1–3, 1989. The first workshop in this series, ‘In Vitro Percutaneous Penetration’, took place in November 1986 (the report of this earlier meeting was published in Pharmaceutical Research , 4 (1987) 265–267). The objectives of the workshop were to review the relevant literature and to address in detail: (1) In vivo percutaneous penetration/absorption methodology; (2) The characteristics of dosage forms designed for application to the skin; (3) Critical factors controlling in vivo drug transport into and across the skin; (4) The use of models in the assessment and evaluation of in vivo percutaneous penetration/absorption; and (5) Bioavailability/bioequivalence considerations for topical drug products. Scientific knowledge and technology are rapidly evolving in the topical and transdermal drug products area. This report focuses on the methodologies available for the measurement of percutaneous penetration in vivo; each scientific approach is discussed briefly followed by advantages and disadvantages of the methodology.


American Journal of Ophthalmology | 1975

Comparative Pharmacologic Effects of Pilocarpine Administered to Normal Subjects by Eyedrops or by Ocular Therapeutic Systems

Virgil A. Place; Myrleen Fisher; Suzanne Herbst; Louis Gordon; Reynold C. Merrill

Normal volunteers used 1, 2, and 4% pilocarpine eyedrops, three times daily, or ocular therapeutic systems placed in the conjunctival cul-de-sac to control intraocular pressure. The systems continuously release 20 and 40 mug/hour of pilocarpine for one week. Although the amount of drug delivered to the eye from the ocular therapeutic system was one fifth that obtained from the eyedrops, the decrease of intraocular pressure was comparable. The ocular therapeutic systems produced small, constant effects on visual acuity, refractive error, and miosis that did not cause visual handicaps or require correction. The effects of eyedrops on these visual factors were large and varied and produced marked visual handicaps that were not correctable with spectacles. Despite its comparable hypotensive effect in normal subjects, continuous delivery of pilocarpine by means of an ocular therapeutic system elicits less severe side effects than pilocarpine eyedrops.


Drug Information Journal | 1975

Patient consent--what makes it informed?

Harriet Benson; Marie Barry; Virgil A. Place

Informed patient consent is a subject explored with increasing frequency in the current legal and medical literature, and a number of guidelines have been set forth for obtaining consent for work with investigational new drugs. Even so, few definitive directions have been available to indicate the best way to ensure informed consent. A recent proposal, ‘The Two-Part Consent Form,” by R. Miller and H. S. Willnerl is of particular interest, since we developed a similar method three years ago to be used in testing therapeutic delivery systems. Our procedure, as described below, has been well received by patients and investigators and offers considerable benefits in obtaining and documenting a patient’s understanding of the clinical study before participation.


Fertility and Sterility | 1974

Progestasert: A Uterine Therapeutic System for Long-term Contraception: I. Philosophy and Clinical Efficacy**Presented at the 29th Annual Meeting of The American Fertility Society, San Francisco, April 5 to 7, 1973.

Bruce B. Pharriss; Ross R. Erickson; John Bashaw; Seymour Hoff; Virgil A. Place; Alejandro Zaffaroni

An intrauterine steroid delivery system the Progestasert system, is described and studies of its clinical efficacy are reported. The Progestasert system combines the advantageous features of IUDs and oral minidose progestogen preparations. An internal device continuously delivers progesterone for 1 year to the uterine lumen and endometrium. A T-shaped Progestasert which releases 65 mcg/day has been selected for wide scale clinical use. A total of 3121 parous women used Progestasert systems for 25,389 woman-months. The pregnancy rate was 1%, the expulsion rate 2.8%, and the total removal rate was 13%. The total continuation rate of the Progestasert system of 83.2% compares favorable with that of the Tatum-T-shaped IUD of 68.7%. These initial results aft er 1 year of use are most encouraging and suggest that the goals originally set for a contraceptive approach using intrauterine progester one are well within reach.


Archive | 1994

Oral osmotic device with hydrogel driving member

Brian Barclay; Jerry D. Childers; Jeri D. Wright; Virgil A. Place; Patrick S. L. Wong


Archive | 1991

Urethral insert for treatment of erectile dysfunction

Virgil A. Place; Robert M. Gale; Randall G. Berggren


Fertility and Sterility | 1974

Progestasert: A Uterine Therapeutic System for Long-term Contraception: I. Philosophy and Clinical Efficacy *

Bruce B. Pharriss; Ross R. Erickson; John Bashaw; Seymour Hoff; Virgil A. Place; Alejandro Zaffaroni


Archive | 1993

Dosage and inserter for treatment of erectile dysfunction

Virgil A. Place; Robert M. Gale; Randall G. Berggren


Archive | 1991

Oral osmotic device for delivering nicotine

Virgil A. Place; Patrick S. L. Wong; Brian Barclay; Jerry D. Childers

Collaboration


Dive into the Virgil A. Place's collaboration.

Researchain Logo
Decentralizing Knowledge